Open Access

Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer

  • Authors:
    • Wenjie Xu
    • Yizhen Wang
    • Yanan Wang
    • Shanmei Lv
    • Xiuping Xu
    • Xuejun Dong
  • View Affiliations

  • Published online on: June 11, 2019     https://doi.org/10.3892/ijmm.2019.4239
  • Pages: 390-404
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aims of the present study were to screen differentially expressed genes (DEGs) in breast cancer (BC) and investigate NDC80 kinetochore complex component (NUF2) as a prognostic marker of BC in detail. A total of four BC microarray datasets, downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, were used to screen DEGs. A total of 190 DEGs with the same expression trends were identified in the 4 datasets, including 65 upregulated and 125 downregulated DEGs. Functional and pathway enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery. The upregulated DEGs were enriched for 10 Gene Ontology (GO) terms and 7 pathways, and the downregulated DEGs were enriched for 10 GO terms and 10 pathways. A protein‑protein interaction network containing 149 nodes and 930 edges was constructed using the Search Tool for the Retrieval of Interacting Genes, and 2 functional modules were identified using the MCODE plugin of Cytoscape. Based on an in‑depth analysis of module 1 and literature mining, NUF2 was selected for further research. Oncomine database analysis and reverse transcription‑quantitative PCR showed that NUF2 is significantly upregulated in BC tissues. In analyses of correlations between NUF2 and clinical pathological characteristics, NUF2 was significantly associated with the malignant features of BC. Using 5 additional datasets from GEO, it was demonstrated that NUF2 has a significant prognostic role in both ER‑positive and ER‑negative BC. A Gene Set Enrichment Analysis indicated that NUF2 may regulate breast carcinogenesis and progression via cell cycle‑related pathways. The results of the present study demonstrated that NUF2 is overexpressed in BC and is significantly associated with its multiple pathological features and prognosis.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Donepudi MS, Kondapalli K, Amos SJ and Venkanteshan P: Breast cancer statistics and markers. J Cancer Res Ther. 10:506–511. 2014.PubMed/NCBI

3 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Tan W, Yang M, Yang H, Zhou F and Shen W: Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 10:4333–4347. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Salem Y, Yacov N, Propheta-Meiran O, Breitbart E and Mendel I: Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis. Int J Cancer. 144:125–135. 2019. View Article : Google Scholar

6 

Kinsella MD, Nassar A, Siddiqui MT and Cohen C: Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience. Int J Clin Exp Pathol. 5:530–536. 2012.

7 

Piao J, Chen L, Jin T, Xu M, Quan C and Lin Z: Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker. Hum Pathol. 73:33–40. 2018. View Article : Google Scholar

8 

Sandoo A, Kitas GD and Carmichael AR: Breast cancer therapy and cardiovascular risk: Focus on trastuzumab. Vasc Health Risk Manag. 11:223–228. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Nabetani A, Koujin T, Tsutsumi C, Haraguchi T and Hiraoka Y: A conserved protein, Nuf2, is implicated in connecting the centromere to the spindle during chromosome segregation: A link between the kinetochore function and the spindle checkpoint. Chromosoma. 110:322–334. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Hu P, Chen X, Sun J, Bie P and Zhang LD: siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 35: pii:e001702015.

11 

Fu HL and Shao L: Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. Eur Rev Med Pharmacol Sci. 20:1071–1079. 2016.PubMed/NCBI

12 

Xiang YJ, Fu Q, Ma ZB, Gao DZ, Zhang Q, Li YY, Li L, Liu L, Ye CM, Yu ZG and Guo MM: Screening for candidate genes related to breast cancer with cDNA microarray analysis. Chronic Dis Transl Med. 1:65–72. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Zhang W, Mao JH, Zhu W, Jain AK, Liu K, Brown JB and Karpen GH: Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nat Commun. 7:126192016. View Article : Google Scholar : PubMed/NCBI

14 

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, et al: Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis. Carcinogenesis. 34:2300–2308. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F, Dubois T, Dutreix M, Vincent-Salomon A, Miller KM and Mechta-Grigoriou F: Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 8:527–549. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S and Dubois T: Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One. 10:e01223332015. View Article : Google Scholar : PubMed/NCBI

17 

Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, et al: Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Res. 74:3114–3126. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Tomczak K, Czerwińska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.

19 

Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953–R964. 2005. View Article : Google Scholar : PubMed/NCBI

20 

Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71:5635–5645. 2011. View Article : Google Scholar : PubMed/NCBI

21 

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Jones SB, DePrimo SE, Whitfield ML and Brooks JD: Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 14:596–604. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Kao KJ, Chang KM, Hsu HC and Huang AT: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. BMC Cancer. 11:1432011. View Article : Google Scholar : PubMed/NCBI

24 

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI

25 

Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar

26 

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI

27 

Doerks T, Copley RR, Schultz J, Ponting CP and Bork P: Systematic identification of novel protein domain families associated with nuclear functions. Genome Res. 12:47–56. 2002. View Article : Google Scholar : PubMed/NCBI

28 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

30 

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Xue D, Cheng P, Han M, Liu X, Xue L, Ye C, Wang K and Huang J: An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer. OncoTargets Ther. 11:4755–4768. 2018. View Article : Google Scholar

32 

Chen L, Yuan L, Qian K, Qian G, Zhu Y, Wu CL, Dan HC, Xiao Y and Wang X: Identification of biomarkers associated with pathological stage and prognosis of clear cell renal cell carcinoma by co-expression network analysis. Front Physiol. 9:3992018. View Article : Google Scholar : PubMed/NCBI

33 

Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B and Oesterreich S: Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res. 20:1062018. View Article : Google Scholar : PubMed/NCBI

34 

Kaushik N, Kim S, Suh Y and Lee SJ: Proinvasive extracellular matrix remodeling for tumor progression. Arch Pharm Res. 42:40–47. 2019. View Article : Google Scholar

35 

Walker C, Mojares E and Del Rio Hernández A: Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 19:pii: E3028. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Tilghman RW, Cowan CR, Mih JD, Koryakina Y, Gioeli D, Slack-Davis JK, Blackman BR, Tschumperlin DJ and Parsons JT: Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS One. 5:e129052010. View Article : Google Scholar : PubMed/NCBI

37 

Yao PL, Morales JL, Zhu B, Kang BH, Gonzalez FJ and Peters JM: Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity. Mol Cancer Ther. 13:1008–1017. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Song W, Yan CY, Zhou QQ and Zhen LL: Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. Biomed Pharmacother. 89:845–856. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P and Getzenberg RH: Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 9:1532011. View Article : Google Scholar : PubMed/NCBI

40 

Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X and Giuliano AE: Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 149:125–129. 2014. View Article : Google Scholar

41 

Ryu JM, Choi HJ, Kim I, Lee SK, Yu J, Kim JE, Kang BI, Lee JE, Nam SJ and Kim SW: Only estrogen receptor 'positive' is not enough to predict the prognosis of breast cancer. Breast Cancer Res Treat. 172:627–636. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Dunnwald LK, Rossing MA and Li CI: Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res. 9:R62007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2019
Volume 44 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, W., Wang, Y., Wang, Y., Lv, S., Xu, X., & Dong, X. (2019). Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer. International Journal of Molecular Medicine, 44, 390-404. https://doi.org/10.3892/ijmm.2019.4239
MLA
Xu, W., Wang, Y., Wang, Y., Lv, S., Xu, X., Dong, X."Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer". International Journal of Molecular Medicine 44.2 (2019): 390-404.
Chicago
Xu, W., Wang, Y., Wang, Y., Lv, S., Xu, X., Dong, X."Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer". International Journal of Molecular Medicine 44, no. 2 (2019): 390-404. https://doi.org/10.3892/ijmm.2019.4239